Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock plunged on Thursday after the company cut its annual guidance.
The diabetes-focused company reported adjusted loss of 78 cents per share, missing the consensus loss of 40 cents.
Tandem reported sales of $240.678 million, up 8% year over year, beating the consensus of $238.57 million.
Shipments in the United States grew to approximately 21,000 pumps. Shipments outside the United States were approximately 9,000 pumps.
Also Read: Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Outlook
Tandem Diabetes narrowed fiscal 2025 sales guidance from $997 million-$1.01 billion to $1 billion compared to the consensus of $1.004 billion.
“Our narrowed guidance reflects insights gained in the first half of the year, including our U.S. growth expectations as we progress our commercial transformation, increased benefit from accelerated pharmacy channel initiatives, and greater contributions from international sales,” said Leigh Vosseller, executive vice president and CFO.
Updated guidance …